Floatz logo

Gm-K562/Leukemia Cell Vaccine

Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts

Dana-Farber Cancer InstitutevaccinePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Gm-K562/Leukemia Cell Vaccine is also rated in:

Chronic Myelomonocytic LeukemiaDormant
CC
Indicative ·
42 / 100
View asset →
Acute Myeloid LeukemiaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →